title: [Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer].
abstract: OBJECTIVE
  Abdominal recurrence from exfoliated cancer cells contributes a lot to treatment failure of advanced gastric cancer. Intraperitoneal chemotherapy, which has been proved effective in eliminating exfoliated cancer cells in abdominal cavity, is a hot topic on treatment of gastric cancer. This study was to explore application of combined therapy of intraoperative hypotonic peritoneal chemo-hyperthermia and early postoperative intraperitoneal chemotherapy to gastric cancer.
  
  
  METHODS
  A total of 156 gastric cancer patients were randomized into 3 groups, and underwent the combined therapy (treatment group 1), intraoperative chemotherapy (treatment group 2), and peritoneal lavage with distilled water (control group), respectively.
  
  
  RESULTS
  The 2-year survival rate of treatment group 1 was significantly higher than that of control group (88.4% vs. 65.2%, P < 0.05). The 3-year survival rate of treatment group 1 was significantly higher than those of treatment group 2, and control group (71.1% vs. 50.0%, and 45.6%, P < 0.05). Occurrence of liver metastasis was significantly lower in treatment groups 1 and 2 than in control group (7.7%, and 10.2% vs. 27.3%, P < 0.05).
  
  
  CONCLUSIONS
  Combined therapy of intraoperative hypotonic chemo-hyperthermia and early postoperative intraperitoneal chemotherapy is effective for gastric cancer. Intraperitoneal chemotherapy can be used to prevent postoperative liver metastasis of gastric cancer.
authors.affiliation: Department of General Surgery, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, P. R. China. wgdr2004@163.com
authors.forename: Guo
authors.initials: G
authors.lastname: Wei
authors.forename: Guo-En
authors.initials: GE
authors.lastname: Fang
authors.forename: Jian-Wei
authors.initials: JW
authors.lastname: Bi
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Shen
authors.forename: Ming-Ming
authors.initials: MM
authors.lastname: Nie
authors.forename: Xu-Chao
authors.initials: XC
authors.lastname: Xue
authors.forename: Ji-De
authors.initials: JD
authors.lastname: Hua
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D005743:Gastrectomy / Q000379:methods; D006801:Humans; D006979:Hyperthermia, Induced; D007038:Hypotonic Solutions / Q000008:administration & dosage; D007263:Infusions, Parenteral; D007430:Intraoperative Care; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010533:Peritoneal Lavage / Q000379:methods; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
chemical_list: D007038:Hypotonic Solutions; D002945:Cisplatin; D005472:Fluorouracil